help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on January 25, 2007, doi:10.1164/rccm.200608-1153CC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200608-1153CCv1
175/9/875    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nathan, S. D.
Right arrow Articles by Tuder, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nathan, S. D.
Right arrow Articles by Tuder, R. M.
American Journal of Respiratory and Critical Care Medicine Vol 175. pp. 875-880, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200608-1153CC

Pulmonary Perspective

Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

Connecting the Dots

Steven D. Nathan1, Paul W. Noble2 and Rubin M. Tuder3

1 Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia; 2 Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University, Durham, North Carolina; and 3 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Correspondence and requests for reprints should be addressed to Steven D. Nathan, M.D., Medical Director, Advanced Lung Disease and Transplant Program, Inova Heart & Vascular Institute, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042. E-mail: steven.nathan{at}inova.com

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and a course that is unpredictable. Pulmonary hypertension may complicate the course of IPF and potentially impact prognosis. There are multiple factors that might influence the onset and severity of pulmonary hypertension in IPF. The relationship between the physiologic and pathobiologic manifestations of the progressive fibrotic process and interceding pulmonary hypertension has not been well defined. This article serves to explore these relationships and to hypothesize about the possible linkage between these entities. From a prognostic standpoint, recent evidence suggests this to be important to assess for pulmonary hypertension in patients with IPF. The appropriate triggers for evaluating for pulmonary hypertension and the best method of detection require further study. Despite the relative ease of noninvasive methods, such as echocardiography, right-heart catheterization remains the best diagnostic test. The appeal of pulmonary hypertension in IPF is that it may be an enticing therapeutic target in a disease that otherwise does not have any proven effective therapies. Which agent(s) might be useful and when they should be implemented mandate the appropriate studies being performed. Some of the data presented in this article have previously been reported in abstract form only.

Key Words: pulmonary fibrosis • hypertension, pulmonary • pulmonary function tests • cytokines




This article has been cited by other articles:


Home page
 RadiologyHome page
A. Devaraj, A. U. Wells, M. G. Meister, T. J. Corte, and D. M. Hansell
The Effect of Diffuse Pulmonary Fibrosis on the Reliability of CT Signs of Pulmonary Hypertension
Radiology, December 1, 2008; 249(3): 1042 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Rich and M. Rabinovitch
Diagnosis and Treatment of Secondary (Non-Category 1) Pulmonary Hypertension
Circulation, November 18, 2008; 118(21): 2190 - 2199.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Eferl, P. Hasselblatt, M. Rath, H. Popper, R. Zenz, V. Komnenovic, M.-H. Idarraga, L. Kenner, and E. F. Wagner
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1
PNAS, July 29, 2008; 105(30): 10525 - 10530.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. E. Daniels, E. S. Yi, and J. H. Ryu
Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis
Eur. Respir. J., July 1, 2008; 32(1): 170 - 174.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Humbert
Update in Pulmonary Arterial Hypertension 2007
Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 574 - 579.
[Full Text] [PDF]

Home page
 ChestHome page
D. A. Zisman, A. S. Karlamangla, S. M. Kawut, O. A. Shlobin, R. Saggar, D. J. Ross, M. I. Schwarz, J. A. Belperio, A. Ardehali, J. P. Lynch III, et al.
Validation of a Method To Screen for Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Chest, March 1, 2008; 133(3): 640 - 645.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez
Pulmonary Diseases and the Heart
Circulation, December 18, 2007; 116(25): 2992 - 3005.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. P. Fadini, M. Schiavon, F. Rea, A. Avogaro, and C. Agostini
Depletion of Endothelial Progenitor Cells May Link Pulmonary Fibrosis and Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 724 - 725.
[Full Text] [PDF]

Home page
 ChestHome page
N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Chest, September 1, 2007; 132(3): 998 - 1006.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society 		  ATS State of the Art Course 2008